Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 4/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 3/20 | 0.31 |
| ▸ | FLT3 | P36888 | 3/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569672 | 0.75 | ADRB1 (0.38) | RIPK1 | |
| Hydrochloric Acid SCHEMBL16569842 | 0.74 | ADRB1 (0.37) | RIPK1 | |
| SCHEMBL16569606 | 0.70 | HRH1 (0.40) | — | |
| SCHEMBL13285783 | 0.69 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL16578759 | 0.69 | KHK (0.35) | CSNK1ERIPK1 | |
| SCHEMBL17975505 | 0.68 | — | — | |
| SCHEMBL16236124 | 0.66 | ALDH1A1 (0.53) | CSNK1ELATS1PRKCQHDAC1 | |
| SCHEMBL23561133 | 0.66 | CDK4 (0.40) | LATS1PRKCQHDAC1 | |
| SCHEMBL17613248 | 0.65 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL82946 | 0.65 | HDAC1 (0.45) | CSNK1ELATS1PRKCQHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | CSNK1E 86/4885LATS1 1243/4885AURKA 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.